国际新闻精选周六（2017年4月1日）

Merrimack Stockholders Approve Sale of ONIVYDE and Generic Version of DOXIL to Ipsen for Up to $1.025 Billion

Merrimack Pharmaceuticals, Inc. (NASDAQ: MACK) ("Merrimack") announced that, at its Special Meeting of Stockholders held today, its stockholders voted to approve the asset sale with Ipsen S.A. under which Merrimack will:

• Sell to Ipsen its first commercial product ONIVYDE®, including U.S. commercialization rights and its licensing agreement with Shire plc; and
• Sell to Ipsen its generic version of doxorubicin hydrochloride (HCI) liposome injection ("generic DOXIL®") marketed in the United States as DOXIL® and advanced under a development, license and supply agreement with Actavis LLC.【阅读全文】

Incyte and Merck Provide Additional Details on Previously Announced Collaboration Investigating Epacadostat and KEYTRUDA (pembrolizumab)

Incyte Corporation (Nasdaq:INCY) and Merck (NYSE:MRK), known as MSD outside the United States and Canada, today announced additional details of their clinical development program investigating the combination of epacadostat, Incyte’s investigational oral selective IDO1 enzyme inhibitor, with KEYTRUDA® (pembrolizumab), Merck’s anti-PD-1 therapy, in patients across five tumor types: metastatic melanoma, non-small cell lung cancer (NSCLC), bladder cancer, renal cell carcinoma (RCC), and squamous cell carcinoma of the head and neck (SCCHN).【阅读全文】

Upcoming events – Ingrezza's approval and data for Shire's new rare disease asset

Welcome to your weekly digest of approaching regulatory and clinical readouts. Neurocrine expects a decision on its tardive dyskinesia candidate Ingrezza by April 11, with speculation that it will be approved fuelled by the cancellation of an advisory committee meeting. However, Teva’s competitor, which is based on the same compound as Ingrezza, looms.【阅读全文】

UPDATED: Kite Pharma hits its Q1 deadline on filing a BLA for its pioneering CAR-T

With the clock ticking down the final hours of Q1, Kite Pharmaceuticals $KITE has kept its pledge to file an application for its pioneering CAR-T therapy in the first quarter. The move puts Kite one step behind Novartis $NVS, which two days ago announced that it had the FDA’s commitment for a speedy review of its own CAR-T.【阅读全文】

Halozyme dips after pancreatic cancer trial halted for futility

Investors have driven down shares in Halozyme Therapeutics following news investigators halted a phase 1b/2 pancreatic cancer trial for futility. The failure of the investigator-initiated trial to show signs of efficacy raised doubts about the ability of PEGPH20 to deliver positive data in phase 3, despite differences in the designs of the studies.【阅读全文】

Takeda cuts 180 Ariad workers as it grabs synergies from $5.2B buyout

Takeda was unambiguous about the importance of cost synergies as a driver of its $5.2 billion buyout of Ariad, mentioning it six times when it announced the deal in January. Those now come into play as the Japanese drugmaker trims about 180 jobs in the Boston area.【阅读全文】

★ 请关注《美中药源》微信公众号 ★